Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma

Simple item page
dc.citation.epage95en_US
dc.citation.issueNumber1en_US
dc.citation.spage88en_US
dc.citation.volumeNumber8en_US
dc.contributor.authorSenses, K. M.en_US
dc.contributor.authorGhasemi M.en_US
dc.contributor.authorAkbar, M. W.en_US
dc.contributor.authorIsbilen, M.en_US
dc.contributor.authorFallacara, A. L.en_US
dc.contributor.authorFrankenburg, S.en_US
dc.contributor.authorSchenone, S.en_US
dc.contributor.authorLotem, M.en_US
dc.contributor.authorBotta, M.en_US
dc.contributor.authorGure, A. O.en_US
dc.date.accessioned2018-04-12T11:07:15Z
dc.date.available2018-04-12T11:07:15Z
dc.date.issued2017en_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractTranscriptomic phenotypes defined for melanoma have been reported to correlate with sensitivity to various drugs. In this study, we aimed to define a minimal signature that could be used to distinguish melanoma sub-types in vitro, and to determine suitable drugs by which these sub-types can be targeted. By using primary melanoma cell lines, as well as commercially available melanoma cell lines, we find that the evaluation of MLANA and INHBA expression is as capable as one based on a combined analysis performed with genes for stemness, EMT and invasion/proliferation, in identifying melanoma subtypes that differ in their sensitivity to molecularly targeted drugs. Using this approach, we find that 75% of melanoma cell lines can be treated with either the MEK inhibitor AZD6244 or the HSP90 inhibitor 17AAG.en_US
dc.identifier.doi10.1039/c6md00466ken_US
dc.identifier.issn2040-2503
dc.identifier.urihttp://hdl.handle.net/11693/37248
dc.language.isoEnglishen_US
dc.publisherRoyal Society of Chemistryen_US
dc.relation.isversionofhttps://doi.org/10.1039/c6md00466ken_US
dc.source.titleMedChemCommen_US
dc.subjectbiological markeren_US
dc.subjectCrizotiniben_US
dc.subjectGlycoprotein gp 100en_US
dc.subjectMelan Aen_US
dc.subjectn (2,3 dihydroxypropoxy) 3,4 difluoro 2 (2 fluoro 4 iodoanilino)benzamideen_US
dc.subjectProtein S 100en_US
dc.subjectSaracatiniben_US
dc.subjectSelumetiniben_US
dc.subjectTanespimycinen_US
dc.subjectCancer classificationen_US
dc.subjectCell invasionen_US
dc.subjectCell proliferationen_US
dc.subjectCell structureen_US
dc.subjectChemosensitivityen_US
dc.subjectControlled studyen_US
dc.subjectCorrelational studyen_US
dc.subjectDrug cytotoxicityen_US
dc.subjectDrug sensitivityen_US
dc.subjectFibroblasten_US
dc.subjectGeneen_US
dc.subjectGene expression profilingen_US
dc.subjectIC50en_US
dc.subjectin vitro studyen_US
dc.subjectINHBA geneen_US
dc.subjectMelanomaen_US
dc.subjectMelanoma cell lineen_US
dc.subjectMLANA geneen_US
dc.subjectMolecularly targeted therapyen_US
dc.subjectPhenotypeen_US
dc.subjectUpregulationen_US
dc.titlePhenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanomaen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Description:
Full printable version
Download

Collections

Department of Molecular Biology and Genetics